Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

Prior treatment

• Have a prior or planned surgical treatment for obesity (excluding Liposuction, Abdominoplasty, or Cryolipolysis, if performed >1 year prior to screening).
• Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laser photocoagulation or intravitreal injections of antivascular endothelial growth factor inhibitors). Note: all participants will have a baseline fundus photography assessment. In the presence of any degree of diabetic retinopathy and/or macular edema, further ophthalmologic assessment will be performed to confirm eligibility.
• Have a self-reported change in body weight >5 kg (11 pounds) within 3 months prior to screening.

Other illness

• Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.

• Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.
• Have a BMI ≥ 27 kg/m2 at screening:
• Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
• Are on stable treatment for T2DM for at least 90 days prior to screening, consisting of: - either diet/exercise alone, or - up to 3 oral antihyperglycemic medications (AHMs) (excluding dipeptidyl peptidase IV inhibitors (DPP-4i) or glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), GLP-1R/GIPR dual agonists, GLP-1R/GIPR/GCGR triple agonists, amylin receptor agonists or GLP-1 receptor and amylin receptor dual agonists)